Persomics, a growing company with innovative solutions that miniaturize, accelerate and increase the scale of phenotypic screening, announced its first custom services agreement with NovellusDx, the leading Precision Cancer Analysis™ company.

Waltham, MA (PRWEB) October 22, 2015

NovellusDx delivers actionable intelligence about the mutational hierarchies that drive each patient's cancer progression together with personalized targeted therapy recommendations. The undisclosed terms of the agreement will leverage the Persomics technology to investigate enhancing functional genomics input into the NovellusDx Precision Cancer Analysis™ platform.

Persomics is commercializing its proprietary miniaturized functional genomics screening technology. Commercial availability of off-the-shelf products are targeted for availability by late 2015 and technology access partnerships with leading life-science companies, CROs, core facilities and academic labs are currently under discussion.

NovellusDx offers in-vitro monitoring of the activity levels of a plurality of signaling pathways originating from patient genes and mutations. Additionally, NovellusDx tests the response of signaling pathways to targeted therapies. Supporting the oncologists with better drugs and drug combinations decisions.

"This agreement reflects Persomics’ interest in strategic collaborations, leveraging our technology to aid partner research” says Neil Emans Ph.D., the CEO of Persomics USA Inc. and the inventor of Persomics technology. 

“NovellusDx will leverage Persomics’ capabilities in our assay” says Yoram Altschuler, Ph.D., CSO of NovellusDx.

Persomics will provide off-the-shelf functional genomics screening tools for routine use in research and screening labs and also engage in collaborative and screening programs with selected partners. Screening tools not available off-the-shelf are easily created and available to partners via custom array printing and screening agreements. In addition, Persomics has enabled specific CROs to use their technology on behalf of their clients.

“We are very excited to launch the Custom Services component of Persomics’ business”, said Mike Sjaastad Ph.D., CCO of Persomics USA Inc., “Persomics is committed to providing access to our technology and services, particularly in expanding utilization faster than we could independently. The potential applications of our miniaturized functional genomics platform extend well beyond RNAi.”

About Persomics
Persomics provides ImagineArraysTM, a technology that miniaturizes, accelerates and increases the scale of phenotypic screening. Researchers investigating the function of the human genome and disease are no longer limited by automation requirements or cost, but by their need to discover more. With Persomics this can be achieved at a fraction of the investment required in large industrial research labs. With our technology the science can go further, faster.
For more information, please visit persomics.com

advertisement | advertise on newsday

About NovellusDx:
NovellusDx, the leading Precision Cancer Analysis™ company, reveals decisive intelligence about mutational hierarchies that govern cancer progression. Oncologists can use this unprecedented level of knowledge to treat patients with precision therapies that are tailored to their cancer.  Access to powerful insights from Precision Cancer Analysis allows bio-pharmaceutical companies to identify new patient groups for their approved therapies and to stratify patients more accurately for efficient clinical studies.
For more information, please visit novellusdx.com

Company Contacts:
 
For Persomics:

Please send enquiries to:
Mike Sjaastad, Ph.D.
CCO, Persomics
mike.sjaastad@persomics.com

For NovellusDx:
Michael Vidne Ph.D.
NovellusDx
michael@novellusdx.com
+972 (0) 29 95 5011

Investor Contact:
David Carey
Lazar Partners
dcarey@lazarpartners.com
212-8671768

For the original version on PRWeb visit: http://www.prweb.com/releases/2015/10/prweb13034790.htm